source
- GSK shelves cough drug acquired in $2B dealMixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.BioPharma Dive · 13d ago↗ source
- How well are AI-discovered drugs faring in the clinic?Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted development.BioPharma Dive · 13d ago↗ source
- GSK drops Phase 3 chronic cough drug in a blow to $2B Bellus Health buyoutIn a major stumble for GSK’s $2 billion acquisition of Bellus Health, the UK pharma said Friday it is ending development of camlipixant in refractory chronic cough (RCC) after the drug ...Endpoints · 13d ago↗ source